Natural Alternatives International Europe, S.A. Receives Swiss Pharmaceutical License

LUGANO, Switzerland, Feb 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Natural Alternatives International Europe, S.A., ("NAIE") a wholly owned subsidiary of Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator and manufacturer of customized nutritional supplements, is pleased to announce that the Swissmedic Authority of Bern, Switzerland has granted to NAIE a pharmaceutical license to process pharmaceuticals for packaging, importation, export, and sale both in Switzerland and internationally, effective January 30, 2004. The license will remain valid until January of 2009.

Dr. Fausto Petrini, Managing Director of NAIE stated, "NAIE, operating in Manno, Switzerland, has primarily focused on non-pharmaceutical nutritional supplement products since initiating production in September 1999. Obtaining the pharmaceutical license certifies that our operations conform to Good Manufacturing Practices. We anticipate this licensure will improve our ability to develop relationships with new customers."

NAI Chairman of the Board and CEO, Mark A. Le Doux, stated, "Achieving this milestone of receiving pharmaceutical licensure from the Swiss Federal government is the result of the leadership of our Swiss and American executive teams and their combined dedication to providing our customers with the highest quality manufacturing expertise. I am very proud of Dr. Fausto Petrini; Randy Weaver, NAI President; Dr. Schwitter, NAIE Quality Assurance Manager; Mark Zimmerman, NAI Vice President of Operations; and many others on both sides of the Atlantic who have worked diligently to receive this license."

NAI, headquartered in San Marcos, California, is a leading formulator and manufacturer of nutritional supplements that provides strategic partnering services to its customers. The Company's comprehensive partnership approach offers a wide range of innovative nutritional products and services to the client including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's intentions, expectations and beliefs concerning future events, including, among other things, expectations and beliefs with respect to the impact upon future financial and operating results from the receipt by NAIE of a pharmaceutical license. The Company wishes to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward- looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including NAI's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.